FDA clearance arms pathologists with digital technology to help assess treatment options for breast cancer patients
PITTSBURGH -- April 14, 2014 -- GE Healthcare and UPMC today announced that the Omnyx™ Manual Read of the Digital HER2 Application has received 510(k) clearance from the U.S. Food and Drug Administration (FDA). This clearance will allow the OmnyxTM system to be marketed in the U.S. for this intended use. Omnyx, LLC is a joint venture of UPMC and GE Healthcare.
Technology can enable clinicians to assess patient's response to treatment accurately
WAUKESHA, Wisc. -- April 8, 2014 -- GE Healthcare, a unit of General Electric Company (NYSE: GE), today announced that it received U.S. FDA 510(k) clearance of its Q.Clear^ technology -- technology that can provide up to two times improvement in both quantitative accuracy and image quality in PET/CT imaging. This is an innovative new tool for clinicians across the entire care continuum including diagnosis, staging, treatment planning, and treatment assessment.
CHALFONT ST. GILES, UK -- 24 March 2014 -- GE (NYSE:GE) announced today that it has completed the acquisition of Thermo Fisher's HyClone™ cell culture media and sera, and gene modulation and magnetic beads businesses. The acquisition allows GE to expand its offering of tools, technologies and services for the discovery and manufacture of innovative new medicines, vaccines and diagnostics in its growing Life Sciences business.
WAUKESHA, Wisc. -- Molecular Breast Imaging (MBI) Clinical Indications, Benefits and Challenges is the focus of a new CME credit course to be offered by ICPME® and funded in part by Gamma Medica, Inc. and in part by GE Healthcare. The one-hour online session will provide a thorough overview of MBI, which is a growing imaging technology for women with dense breasts and certain difficult-to-image cancers.
